外資祕密買入一個消費品牛股
本文來自格隆匯專欄：海榕財富風險投研，作者： 海榕君
5月24日捨得白酒下午漲停，在上漲4倍以後還能漲停我比較意外，捨得白酒盤後公佈了 龍虎榜：
龍虎榜是A股獨立特色的信息披露規則，主要是對股價大幅度波動的股票披露詳細的交易信息。今天捨得白酒在買二席位是 瑞銀證券上海花園石橋路，這個席位買入1.2億 人民幣。這個席位是外資大本營之一 ，買入背後的機構可能是淡馬錫，高瓴資本 ，奧本海默。
為什麼這些機構昨日才買入？因為大部分公募，私募，外資對買入的公司都有要求，對於加了ST的股票是不允許買入的，捨得摘帽以後，昨日是強行上車，算“追高”買入。外資持股週期比較長，即使短期高估，但是長期邏輯好，他們也願意持有 。
説説估值 ，現在國內有 7家賣方分析師跟蹤捨得，對於2021年的淨利潤 展望 利潤是 10億人民幣左右，按1季度披露的業績算預期今年會有12億人民幣的利潤，現在捨得的市值是635億人民幣 ，對應估值是53倍PE 。這個估值不算便宜，沒有持有的投資者也不建議追高買入了。
再説説5月24日的市場：
長春高新和安科生物繼續放量大跌，主要還是我昨天説的幾個不確定性，加上估值比較高。健帆生物 也因為集採風險大幅度下跌 ，這種高位受集採壓力的公司先不要買了 ，風險比較大，從這部分出來的一部分資金在流入 保健茅湯臣倍健。
牧原股份昨日放量大跌，主要源於管理層稱：公司稱做好迎接行業冬天來臨準備。豬肉股和其他商品股一樣都是有周期的，牧原的優勢是養殖成本低，在每次行業底部，都能提高市佔率 ，不建議抄底 牧原股份，可以等一段時間。
短期投資者可以關注疫苗股，港股 中國生物製藥(01177)披露一季報：“應占聯營公司及一家合營公司”的盈利約14.76億元，估計其中大部分是它持有的科興中維的15.03%的股權所應占的盈利，預計科興中維 一季度淨利潤在98億人民幣左右。疫苗股有利好，前期新冠疫苗不賺錢的邏輯證偽，利好國內的沃森生物 ，智飛生物 ，康泰生物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
